Non-compaction cardiomyopathy (NCCM) is a heterogeneous, poorly understood disorder characterized by a prominent inner layer of loose myocardial tissue, and associated with heart failure, stroke, severe rhythm irregularities and death. For a growing population diagnosed with NCCM there is a need for better risk stratification to appropriately allocate (or safely withhold) these impactful preventive measures. The goal of this international consortium is to improve care of patients with non-compaction cardiomyopathy. We hypothesize that comprehensive analysis of clinical, genetic, structural and functional information will improve risk stratification. In addition, we hypothesize that detailed structural analysis will allow for differentiation of pathological and benign patterns of non-compaction. In a large cohort of adult patients with suspected NCCM we will perform in-depth phenotyping, including clinical information, pedigree data, genetics, echocardiography and MRI, and follow patients for up to 3 years. We will apply machine-learning based analytics to develop predictive models and compare their performance to currently used models and treatment criteria. Secondly, in a subset of patients we will perform high-resolution cardiac CT for detailed structural characterization of the myocardial wall. We will investigate associations between myocardial structure and regional contractile function, as assessed by echo and MRI. The aim of this proposal is to identify a structural signature associated with pathological non-compaction and improve developed risk prediction models. Discovery of pathological structural signatures through innovative imaging techniques, in relation to myocardial contractility, will advance our understanding of NCCM.
Study Type
OBSERVATIONAL
Enrollment
600
Standard echocardiography exam performed as part of clinical management.
Standard comprehensive cardiac MRI exam of the heart performed as part of clinical management.
ECG-triggered, contrast-enhanced CT scan of the heart performed for research purposes in eligible study participants.
Stanford University
Palo Alto, California, United States
RECRUITINGCleveland Clinic Foundation
Cleveland, Ohio, United States
RECRUITINGUniversity of Pennsylvania
Philadelphia, Pennsylvania, United States
RECRUITINGErasmus Medical Center
Rotterdam, Netherlands
RECRUITINGSeoul National University Hospital
Seoul, South Korea
RECRUITINGIncidence of hard embolic adverse events
Clinical neuro/systemic embolic event by autopsy, imaging or specialist evaluation
Time frame: Up to 4 years after enrollment
Incidence of hard arrhythmic adverse events
Sudden death (aborted), appropriate ICD discharge or VT/VF on ECG or rhythm/device monitoring
Time frame: Up to 4 years after enrollment
Incidence of hard heart failure related adverse events
Heart failure death, cardiac transplantation or mechanical circulatory support
Time frame: Up to 4 years after enrollment
Incidence of composite of hard adverse events
Hard embolic, arrhythmic and heart failure related adverse events (as described above)
Time frame: Up to 4 years after enrollment
Incidence of all embolic adverse events
Hard embolic adverse events or transient neurologic event without objective infarction
Time frame: Up to 4 years after enrollment
Incidence of all arrhythmic adverse events
Hard arrhythmic adverse events or syncope without recorded arrhythmia
Time frame: Up to 4 years after enrollment
Incidence of all heart failure related adverse events
Hard heart failure related adverse events or resynchronization therapy, heart failure hospital admission
Time frame: Up to 4 years after enrollment
Incidence of composite of adverse events
All embolic, arrhythmic or heart failure related adverse events (as described above)
Time frame: Up to 4 years after enrollment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.